369
Participants
Start Date
January 2, 2025
Primary Completion Date
May 3, 2030
Study Completion Date
May 3, 2030
Cemiplimab
Administered per protocol
Standard of care
Primary surgery
RECRUITING
The Skin Hospital, Darlinghurst
RECRUITING
Westmead Hospital, Westmead
RECRUITING
Dermatology Institute of Victoria (DIV), South Yarra
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Fremantle Dermatology, Fremantle
RECRUITING
Rochester Dermatologic Surgery, P.C., Victor
RECRUITING
Penn State Hershey Medical Center, Hershey
RECRUITING
George Washington University Medical Faculty Associates, Washington D.C.
RECRUITING
Clinical Research Center of the Carolinas, Charleston
RECRUITING
Dermatology Associates of the Palm Beaches, Delray Beach
RECRUITING
University of South Florida, St. Petersburg
RECRUITING
Dawes Fretzin Clinical Research - Shadeland Ave., Indianapolis
RECRUITING
Somerset Skin Centre, Troy
RECRUITING
Oak Dermatology, Naperville
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
Washington University in St. Louis - Center for Dermatologic and Cosmetic Surgery, St Louis
RECRUITING
Arkansas Research Trials, North Little Rock
RECRUITING
Epiphany Dermatology, Lewisville
RECRUITING
Reveal Research Institute, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Texas Dermatology and Laser Specialists, San Antonio
RECRUITING
The University of Texas at Austin Dell Medical School Ascension Medical Group, Austin
RECRUITING
Medical Dermatology Specialists, Phoenix
RECRUITING
Mayo Clinic - Arizona, Scottsdale
RECRUITING
University of New Mexico, Albuquerque
RECRUITING
Las Vegas Dermatology, Las Vegas
RECRUITING
Stanford University, Redwood City
RECRUITING
Dermatology Health Specialists, Bend
RECRUITING
University Skin Oncologists Inc, Beverly
RECRUITING
Dana-Farber Cancer Institute, Boston
Regeneron Pharmaceuticals
INDUSTRY